<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>MP</title>
  <meta name="description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook.">
  <meta name="generator" content="bookdown 0.7 and GitBook 2.6.7">

  <meta property="og:title" content="MP" />
  <meta property="og:type" content="book" />
  
  
  <meta property="og:description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook." />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="MP" />
  
  <meta name="twitter:description" content="This is a minimal example of using the bookdown package to write a book. The output format for this example is bookdown::gitbook." />
  

<meta name="author" content="pqi">



  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="sbrt.html">
<link rel="next" href="implants.html">
<script src="libs/jquery-2.2.3/jquery.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />







<script src="libs/kePrint-0.0.1/kePrint.js"></script>



<link rel="stylesheet" href="style.css" type="text/css" />
<link rel="stylesheet" href="font-awesome.min.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Practical Medical Physics</a></li>

<li class="divider"></li>
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Welcome</a></li>
<li class="chapter" data-level="1" data-path="introduction.html"><a href="introduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a><ul>
<li class="chapter" data-level="1.1" data-path="introduction.html"><a href="introduction.html#constant"><i class="fa fa-check"></i><b>1.1</b> Physics constants</a></li>
<li class="chapter" data-level="1.2" data-path="introduction.html"><a href="introduction.html#atomic-rep"><i class="fa fa-check"></i><b>1.2</b> Atomic Representation</a></li>
<li class="chapter" data-level="1.3" data-path="introduction.html"><a href="introduction.html#stability"><i class="fa fa-check"></i><b>1.3</b> Stability</a></li>
<li class="chapter" data-level="1.4" data-path="introduction.html"><a href="introduction.html#mass-defect"><i class="fa fa-check"></i><b>1.4</b> Mass Defect</a></li>
<li class="chapter" data-level="1.5" data-path="introduction.html"><a href="introduction.html#einstein"><i class="fa fa-check"></i><b>1.5</b> High energy charged particles</a></li>
<li class="chapter" data-level="1.6" data-path="introduction.html"><a href="introduction.html#high-energy-photons"><i class="fa fa-check"></i><b>1.6</b> High energy photons</a></li>
<li class="chapter" data-level="1.7" data-path="introduction.html"><a href="introduction.html#electron-shell"><i class="fa fa-check"></i><b>1.7</b> Electron Shell</a></li>
<li class="chapter" data-level="1.8" data-path="introduction.html"><a href="introduction.html#solutions"><i class="fa fa-check"></i><b>1.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="nut.html"><a href="nut.html"><i class="fa fa-check"></i><b>2</b> Nuclear Transformation</a><ul>
<li class="chapter" data-level="2.1" data-path="nut.html"><a href="nut.html#decays"><i class="fa fa-check"></i><b>2.1</b> Decay (disintegration)</a><ul>
<li class="chapter" data-level="2.1.1" data-path="nut.html"><a href="nut.html#alpha"><i class="fa fa-check"></i><b>2.1.1</b> Alpha-decay</a></li>
<li class="chapter" data-level="2.1.2" data-path="nut.html"><a href="nut.html#beta"><i class="fa fa-check"></i><b>2.1.2</b> Beta-decay</a></li>
<li class="chapter" data-level="2.1.3" data-path="nut.html"><a href="nut.html#ec"><i class="fa fa-check"></i><b>2.1.3</b> Electron capture</a></li>
<li class="chapter" data-level="2.1.4" data-path="nut.html"><a href="nut.html#gamma"><i class="fa fa-check"></i><b>2.1.4</b> Gamma decay</a></li>
</ul></li>
<li class="chapter" data-level="2.2" data-path="nut.html"><a href="nut.html#activity"><i class="fa fa-check"></i><b>2.2</b> Activity</a></li>
<li class="chapter" data-level="2.3" data-path="nut.html"><a href="nut.html#decay-unit"><i class="fa fa-check"></i><b>2.3</b> Unit</a></li>
<li class="chapter" data-level="2.4" data-path="nut.html"><a href="nut.html#nucl-solution"><i class="fa fa-check"></i><b>2.4</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="prox.html"><a href="prox.html"><i class="fa fa-check"></i><b>3</b> Production of X-rays</a><ul>
<li class="chapter" data-level="3.1" data-path="prox.html"><a href="prox.html#history"><i class="fa fa-check"></i><b>3.1</b> History</a></li>
<li class="chapter" data-level="3.2" data-path="prox.html"><a href="prox.html#conventional-x-ray-tubes"><i class="fa fa-check"></i><b>3.2</b> Conventional x-ray tubes</a><ul>
<li class="chapter" data-level="3.2.1" data-path="prox.html"><a href="prox.html#electron-source"><i class="fa fa-check"></i><b>3.2.1</b> Electron Source</a></li>
<li class="chapter" data-level="3.2.2" data-path="prox.html"><a href="prox.html#high-voltage"><i class="fa fa-check"></i><b>3.2.2</b> High voltage</a></li>
</ul></li>
<li class="chapter" data-level="3.3" data-path="prox.html"><a href="prox.html#x-ray-spectra"><i class="fa fa-check"></i><b>3.3</b> X-ray spectra</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="gene.html"><a href="gene.html"><i class="fa fa-check"></i><b>4</b> Clinical Treatment Generators</a><ul>
<li class="chapter" data-level="4.1" data-path="gene.html"><a href="gene.html#history-1"><i class="fa fa-check"></i><b>4.1</b> History</a></li>
<li class="chapter" data-level="4.2" data-path="gene.html"><a href="gene.html#waveguide"><i class="fa fa-check"></i><b>4.2</b> Waveguide</a></li>
<li class="chapter" data-level="4.3" data-path="gene.html"><a href="gene.html#microwave-amplifier"><i class="fa fa-check"></i><b>4.3</b> Microwave amplifier</a></li>
<li class="chapter" data-level="4.4" data-path="gene.html"><a href="gene.html#microwave-frequency"><i class="fa fa-check"></i><b>4.4</b> Microwave frequency</a></li>
<li class="chapter" data-level="4.5" data-path="gene.html"><a href="gene.html#penumbra"><i class="fa fa-check"></i><b>4.5</b> Penumbra</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="inter.html"><a href="inter.html"><i class="fa fa-check"></i><b>5</b> Interaction</a><ul>
<li class="chapter" data-level="5.1" data-path="inter.html"><a href="inter.html#photo-el"><i class="fa fa-check"></i><b>5.1</b> Photoelectric interactions</a></li>
<li class="chapter" data-level="5.2" data-path="inter.html"><a href="inter.html#compton"><i class="fa fa-check"></i><b>5.2</b> Compton interactions</a></li>
<li class="chapter" data-level="5.3" data-path="inter.html"><a href="inter.html#pair"><i class="fa fa-check"></i><b>5.3</b> Pair production</a></li>
<li class="chapter" data-level="5.4" data-path="inter.html"><a href="inter.html#compton-interactions"><i class="fa fa-check"></i><b>5.4</b> Compton interactions</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="measurement.html"><a href="measurement.html"><i class="fa fa-check"></i><b>6</b> Measurement of Ionizing Radiation</a><ul>
<li class="chapter" data-level="6.1" data-path="measurement.html"><a href="measurement.html#collection-volume"><i class="fa fa-check"></i><b>6.1</b> Collection volume</a></li>
<li class="chapter" data-level="6.2" data-path="measurement.html"><a href="measurement.html#signal-of-an-ion-chamber"><i class="fa fa-check"></i><b>6.2</b> Signal of an ion chamber</a></li>
<li class="chapter" data-level="6.3" data-path="measurement.html"><a href="measurement.html#temperature-and-pressure-correction"><i class="fa fa-check"></i><b>6.3</b> Temperature and pressure correction</a></li>
<li class="chapter" data-level="6.4" data-path="measurement.html"><a href="measurement.html#guard-electrode"><i class="fa fa-check"></i><b>6.4</b> Guard electrode</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="quality.html"><a href="quality.html"><i class="fa fa-check"></i><b>7</b> Quality of X-rays</a></li>
<li class="chapter" data-level="8" data-path="dose.html"><a href="dose.html"><i class="fa fa-check"></i><b>8</b> Absorbed Dose</a><ul>
<li class="chapter" data-level="8.1" data-path="dose.html"><a href="dose.html#optical-density"><i class="fa fa-check"></i><b>8.1</b> Optical density</a></li>
<li class="chapter" data-level="8.2" data-path="dose.html"><a href="dose.html#q9-od"><i class="fa fa-check"></i><b>8.2</b> Q9 OD</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="distribution.html"><a href="distribution.html"><i class="fa fa-check"></i><b>9</b> Dose Distributions</a><ul>
<li class="chapter" data-level="9.1" data-path="distribution.html"><a href="distribution.html#tar"><i class="fa fa-check"></i><b>9.1</b> TAR</a></li>
</ul></li>
<li class="chapter" data-level="10" data-path="dosecalc.html"><a href="dosecalc.html"><i class="fa fa-check"></i><b>10</b> Dose calcuation</a></li>
<li class="chapter" data-level="11" data-path="planning1.html"><a href="planning1.html"><i class="fa fa-check"></i><b>11</b> Treatment Planning I: Isodose Distribution and Plan Evaluation</a><ul>
<li class="chapter" data-level="11.1" data-path="planning1.html"><a href="planning1.html#penumbra-1"><i class="fa fa-check"></i><b>11.1</b> Penumbra</a></li>
<li class="chapter" data-level="11.2" data-path="planning1.html"><a href="planning1.html#wedges"><i class="fa fa-check"></i><b>11.2</b> Wedges</a></li>
</ul></li>
<li class="chapter" data-level="12" data-path="planning2.html"><a href="planning2.html"><i class="fa fa-check"></i><b>12</b> Treatment Planning II: Patient Data, Corrections, and Setup</a><ul>
<li class="chapter" data-level="12.1" data-path="planning2.html"><a href="planning2.html#inhomogeneity"><i class="fa fa-check"></i><b>12.1</b> Inhomogeneity</a></li>
<li class="chapter" data-level="12.2" data-path="planning2.html"><a href="planning2.html#range"><i class="fa fa-check"></i><b>12.2</b> Range</a></li>
<li class="chapter" data-level="12.3" data-path="planning2.html"><a href="planning2.html#mri"><i class="fa fa-check"></i><b>12.3</b> MRI</a></li>
<li class="chapter" data-level="12.4" data-path="planning2.html"><a href="planning2.html#pet"><i class="fa fa-check"></i><b>12.4</b> PET</a></li>
</ul></li>
<li class="chapter" data-level="13" data-path="planning3.html"><a href="planning3.html"><i class="fa fa-check"></i><b>13</b> Treatment Planning III: Field shaping, skin dose, and field separation</a><ul>
<li class="chapter" data-level="13.1" data-path="planning3.html"><a href="planning3.html#hvl"><i class="fa fa-check"></i><b>13.1</b> HVL</a></li>
<li class="chapter" data-level="13.2" data-path="planning3.html"><a href="planning3.html#q2-3-4-and-7-range"><i class="fa fa-check"></i><b>13.2</b> Q2, 3, 4, and 7 Range</a></li>
</ul></li>
<li class="chapter" data-level="14" data-path="electron.html"><a href="electron.html"><i class="fa fa-check"></i><b>14</b> Electron</a><ul>
<li class="chapter" data-level="14.1" data-path="electron.html"><a href="electron.html#history-2"><i class="fa fa-check"></i><b>14.1</b> History</a></li>
<li class="chapter" data-level="14.2" data-path="electron.html"><a href="electron.html#treatment-sites"><i class="fa fa-check"></i><b>14.2</b> Treatment Sites</a></li>
<li class="chapter" data-level="14.3" data-path="electron.html"><a href="electron.html#e-interactions"><i class="fa fa-check"></i><b>14.3</b> Interactions</a></li>
<li class="chapter" data-level="14.4" data-path="electron.html"><a href="electron.html#e-delivery"><i class="fa fa-check"></i><b>14.4</b> Delivery</a></li>
<li class="chapter" data-level="14.5" data-path="electron.html"><a href="electron.html#beam-quality"><i class="fa fa-check"></i><b>14.5</b> Beam quality</a></li>
<li class="chapter" data-level="14.6" data-path="electron.html"><a href="electron.html#internal-shielding"><i class="fa fa-check"></i><b>14.6</b> Internal shielding</a></li>
<li class="chapter" data-level="14.7" data-path="electron.html"><a href="electron.html#total-skin-electron-irradiation-tsei"><i class="fa fa-check"></i><b>14.7</b> Total skin electron irradiation (TSEI)</a></li>
<li class="chapter" data-level="14.8" data-path="electron.html"><a href="electron.html#e-solu"><i class="fa fa-check"></i><b>14.8</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="15" data-path="brachy.html"><a href="brachy.html"><i class="fa fa-check"></i><b>15</b> Brachytherapy</a><ul>
<li class="chapter" data-level="15.1" data-path="brachy.html"><a href="brachy.html#important-things-to-know"><i class="fa fa-check"></i><b>15.1</b> Important things to know</a></li>
<li class="chapter" data-level="15.2" data-path="brachy.html"><a href="brachy.html#isotopes"><i class="fa fa-check"></i><b>15.2</b> Isotopes</a><ul>
<li class="chapter" data-level="15.2.1" data-path="brachy.html"><a href="brachy.html#radium-sources"><i class="fa fa-check"></i><b>15.2.1</b> Radium sources</a></li>
<li class="chapter" data-level="15.2.2" data-path="brachy.html"><a href="brachy.html#radium-substitutes"><i class="fa fa-check"></i><b>15.2.2</b> Radium substitutes</a></li>
</ul></li>
<li class="chapter" data-level="15.3" data-path="brachy.html"><a href="brachy.html#source-strength"><i class="fa fa-check"></i><b>15.3</b> Source strength</a><ul>
<li class="chapter" data-level="15.3.1" data-path="brachy.html"><a href="brachy.html#sk"><i class="fa fa-check"></i><b>15.3.1</b> Unit: Air-kerma strength <span class="math inline">\(S_k\)</span></a></li>
</ul></li>
<li class="chapter" data-level="15.4" data-path="brachy.html"><a href="brachy.html#radiation-dose-from-brachytherpay-sources"><i class="fa fa-check"></i><b>15.4</b> Radiation dose from brachytherpay sources</a><ul>
<li class="chapter" data-level="15.4.1" data-path="brachy.html"><a href="brachy.html#from-exposure-rate"><i class="fa fa-check"></i><b>15.4.1</b> From exposure rate</a></li>
<li class="chapter" data-level="15.4.2" data-path="brachy.html"><a href="brachy.html#tg43"><i class="fa fa-check"></i><b>15.4.2</b> TG-43</a></li>
</ul></li>
<li class="chapter" data-level="15.5" data-path="brachy.html"><a href="brachy.html#ldr-solutions"><i class="fa fa-check"></i><b>15.5</b> Solutions</a></li>
<li class="chapter" data-level="15.6" data-path="brachy.html"><a href="brachy.html#traceability"><i class="fa fa-check"></i><b>15.6</b> Traceability</a></li>
<li class="chapter" data-level="15.7" data-path="brachy.html"><a href="brachy.html#tg-167"><i class="fa fa-check"></i><b>15.7</b> TG-167</a></li>
</ul></li>
<li class="chapter" data-level="16" data-path="protection.html"><a href="protection.html"><i class="fa fa-check"></i><b>16</b> Radiation Protection</a><ul>
<li class="chapter" data-level="16.1" data-path="protection.html"><a href="protection.html#sources-of-radiation-exposure"><i class="fa fa-check"></i><b>16.1</b> Sources of radiation exposure</a></li>
<li class="chapter" data-level="16.2" data-path="protection.html"><a href="protection.html#stochastic-and-deterministic-event"><i class="fa fa-check"></i><b>16.2</b> Stochastic and deterministic event</a></li>
<li class="chapter" data-level="16.3" data-path="protection.html"><a href="protection.html#tds-rule"><i class="fa fa-check"></i><b>16.3</b> TDS rule</a></li>
</ul></li>
<li class="chapter" data-level="17" data-path="qa.html"><a href="qa.html"><i class="fa fa-check"></i><b>17</b> QA</a><ul>
<li class="chapter" data-level="17.1" data-path="qa.html"><a href="qa.html#tg-100"><i class="fa fa-check"></i><b>17.1</b> TG-100</a></li>
<li class="chapter" data-level="17.2" data-path="qa.html"><a href="qa.html#tg-275"><i class="fa fa-check"></i><b>17.2</b> TG-275</a></li>
</ul></li>
<li class="chapter" data-level="18" data-path="tbi.html"><a href="tbi.html"><i class="fa fa-check"></i><b>18</b> TBI</a></li>
<li class="chapter" data-level="19" data-path="crt.html"><a href="crt.html"><i class="fa fa-check"></i><b>19</b> Three-dimensional conformal radiotherapy</a><ul>
<li class="chapter" data-level="19.1" data-path="crt.html"><a href="crt.html#icru-reference-point"><i class="fa fa-check"></i><b>19.1</b> ICRU reference point</a></li>
<li class="chapter" data-level="19.2" data-path="crt.html"><a href="crt.html#image-registration"><i class="fa fa-check"></i><b>19.2</b> Image registration</a></li>
<li class="chapter" data-level="19.3" data-path="crt.html"><a href="crt.html#image-segmentation"><i class="fa fa-check"></i><b>19.3</b> Image segmentation</a></li>
<li class="chapter" data-level="19.4" data-path="crt.html"><a href="crt.html#cumulative-dvh"><i class="fa fa-check"></i><b>19.4</b> Cumulative DVH</a></li>
<li class="chapter" data-level="19.5" data-path="crt.html"><a href="crt.html#differential-dvh"><i class="fa fa-check"></i><b>19.5</b> Differential DVH</a></li>
</ul></li>
<li class="chapter" data-level="20" data-path="imrt.html"><a href="imrt.html"><i class="fa fa-check"></i><b>20</b> IMRT</a><ul>
<li class="chapter" data-level="20.1" data-path="imrt.html"><a href="imrt.html#imrt"><i class="fa fa-check"></i><b>20.1</b> IMRT</a></li>
<li class="chapter" data-level="20.2" data-path="imrt.html"><a href="imrt.html#patient-specific-plan-qa-pspa-or-imrt-qa"><i class="fa fa-check"></i><b>20.2</b> Patient-specific Plan QA (PSPA) or IMRT QA</a><ul>
<li class="chapter" data-level="20.2.1" data-path="imrt.html"><a href="imrt.html#devices"><i class="fa fa-check"></i><b>20.2.1</b> Devices</a></li>
<li class="chapter" data-level="20.2.2" data-path="imrt.html"><a href="imrt.html#evaluation-methods-hccf_documents_qaspecific-imrt-qa.doc"><i class="fa fa-check"></i><b>20.2.2</b> Evaluation methods (H:CCF_DOCUMENTS_qaSpecific IMRT QA.doc)</a></li>
</ul></li>
<li class="chapter" data-level="20.3" data-path="imrt.html"><a href="imrt.html#transmission-or-leakage"><i class="fa fa-check"></i><b>20.3</b> Transmission or leakage</a></li>
<li class="chapter" data-level="20.4" data-path="imrt.html"><a href="imrt.html#q4-mu-imrt-vs.3dcrt"><i class="fa fa-check"></i><b>20.4</b> Q4 MU: IMRT vs. 3DCRT</a></li>
<li class="chapter" data-level="20.5" data-path="imrt.html"><a href="imrt.html#q5"><i class="fa fa-check"></i><b>20.5</b> Q5</a></li>
<li class="chapter" data-level="20.6" data-path="imrt.html"><a href="imrt.html#shielding-for-imrt"><i class="fa fa-check"></i><b>20.6</b> Shielding for IMRT</a></li>
<li class="chapter" data-level="20.7" data-path="imrt.html"><a href="imrt.html#section"><i class="fa fa-check"></i><b>20.7</b> </a></li>
<li class="chapter" data-level="20.8" data-path="imrt.html"><a href="imrt.html#q8"><i class="fa fa-check"></i><b>20.8</b> Q8</a></li>
<li class="chapter" data-level="20.9" data-path="imrt.html"><a href="imrt.html#q9"><i class="fa fa-check"></i><b>20.9</b> Q9</a></li>
<li class="chapter" data-level="20.10" data-path="imrt.html"><a href="imrt.html#q10"><i class="fa fa-check"></i><b>20.10</b> Q10</a></li>
<li class="chapter" data-level="20.11" data-path="imrt.html"><a href="imrt.html#mlc-tests"><i class="fa fa-check"></i><b>20.11</b> MLC test(s)</a></li>
<li class="chapter" data-level="20.12" data-path="imrt.html"><a href="imrt.html#q12"><i class="fa fa-check"></i><b>20.12</b> Q12</a></li>
</ul></li>
<li class="chapter" data-level="21" data-path="sbrt.html"><a href="sbrt.html"><i class="fa fa-check"></i><b>21</b> SBRT</a><ul>
<li class="chapter" data-level="21.1" data-path="sbrt.html"><a href="sbrt.html#milestones"><i class="fa fa-check"></i><b>21.1</b> Milestones</a></li>
<li class="chapter" data-level="21.2" data-path="sbrt.html"><a href="sbrt.html#the-definition-of-srs-and-sbrt"><i class="fa fa-check"></i><b>21.2</b> The definition of SRS and SBRT</a></li>
<li class="chapter" data-level="21.3" data-path="sbrt.html"><a href="sbrt.html#features-of-gamma-knife-perfexiontm-and-icontm"><i class="fa fa-check"></i><b>21.3</b> Features of GAMMA Knife Perfexion<sup>TM</sup> and Icon<sup>TM</sup></a><ul>
<li class="chapter" data-level="21.3.1" data-path="sbrt.html"><a href="sbrt.html#stereotactic-reference"><i class="fa fa-check"></i><b>21.3.1</b> Stereotactic reference</a></li>
<li class="chapter" data-level="21.3.2" data-path="sbrt.html"><a href="sbrt.html#steps-to-create-new-plan"><i class="fa fa-check"></i><b>21.3.2</b> Steps to create new plan</a></li>
</ul></li>
<li class="chapter" data-level="21.4" data-path="sbrt.html"><a href="sbrt.html#gk-troubleshooting"><i class="fa fa-check"></i><b>21.4</b> GK Troubleshooting</a></li>
<li class="chapter" data-level="21.5" data-path="sbrt.html"><a href="sbrt.html#qa-of-gk"><i class="fa fa-check"></i><b>21.5</b> QA of GK</a><ul>
<li class="chapter" data-level="21.5.1" data-path="sbrt.html"><a href="sbrt.html#prescision-and-accuracy"><i class="fa fa-check"></i><b>21.5.1</b> Prescision and accuracy</a></li>
</ul></li>
<li class="chapter" data-level="21.6" data-path="sbrt.html"><a href="sbrt.html#commissioning-of-gk"><i class="fa fa-check"></i><b>21.6</b> Commissioning of GK</a></li>
<li class="chapter" data-level="21.7" data-path="sbrt.html"><a href="sbrt.html#preparation-of-gk-treatment-planning"><i class="fa fa-check"></i><b>21.7</b> Preparation of GK Treatment Planning</a><ul>
<li class="chapter" data-level="21.7.1" data-path="sbrt.html"><a href="sbrt.html#frame-application-model-c"><i class="fa fa-check"></i><b>21.7.1</b> Frame Application: model C</a></li>
<li class="chapter" data-level="21.7.2" data-path="sbrt.html"><a href="sbrt.html#frame-application-perfexion"><i class="fa fa-check"></i><b>21.7.2</b> Frame application: Perfexion</a></li>
</ul></li>
<li class="chapter" data-level="21.8" data-path="sbrt.html"><a href="sbrt.html#gk-plan-indices"><i class="fa fa-check"></i><b>21.8</b> GK Plan Indices</a><ul>
<li class="chapter" data-level="21.8.1" data-path="sbrt.html"><a href="sbrt.html#systematic-errors"><i class="fa fa-check"></i><b>21.8.1</b> Systematic Errors</a></li>
</ul></li>
<li class="chapter" data-level="21.9" data-path="sbrt.html"><a href="sbrt.html#linac-based-srs"><i class="fa fa-check"></i><b>21.9</b> Linac-based SRS</a><ul>
<li class="chapter" data-level="21.9.1" data-path="sbrt.html"><a href="sbrt.html#cone-based"><i class="fa fa-check"></i><b>21.9.1</b> Cone-based</a></li>
</ul></li>
<li class="chapter" data-level="21.10" data-path="sbrt.html"><a href="sbrt.html#diesease-sites-treatment-with-srs"><i class="fa fa-check"></i><b>21.10</b> Diesease sites treatment with SRS</a><ul>
<li class="chapter" data-level="21.10.1" data-path="sbrt.html"><a href="sbrt.html#acoustic-neuoromas"><i class="fa fa-check"></i><b>21.10.1</b> Acoustic neuoromas</a></li>
<li class="chapter" data-level="21.10.2" data-path="sbrt.html"><a href="sbrt.html#arteriovenous-malforamtions-avm"><i class="fa fa-check"></i><b>21.10.2</b> Arteriovenous malforamtions (AVM)</a></li>
<li class="chapter" data-level="21.10.3" data-path="sbrt.html"><a href="sbrt.html#brain-metastases"><i class="fa fa-check"></i><b>21.10.3</b> Brain metastases</a></li>
<li class="chapter" data-level="21.10.4" data-path="sbrt.html"><a href="sbrt.html#malignant-gliomas"><i class="fa fa-check"></i><b>21.10.4</b> Malignant gliomas</a></li>
<li class="chapter" data-level="21.10.5" data-path="sbrt.html"><a href="sbrt.html#menningiomas"><i class="fa fa-check"></i><b>21.10.5</b> Menningiomas</a></li>
<li class="chapter" data-level="21.10.6" data-path="sbrt.html"><a href="sbrt.html#pituitary-tumors"><i class="fa fa-check"></i><b>21.10.6</b> Pituitary tumors</a></li>
<li class="chapter" data-level="21.10.7" data-path="sbrt.html"><a href="sbrt.html#unilateral-vestibular-schwannomas"><i class="fa fa-check"></i><b>21.10.7</b> Unilateral Vestibular Schwannomas</a></li>
<li class="chapter" data-level="21.10.8" data-path="sbrt.html"><a href="sbrt.html#uveal-melanomas"><i class="fa fa-check"></i><b>21.10.8</b> Uveal melanomas</a></li>
<li class="chapter" data-level="21.10.9" data-path="sbrt.html"><a href="sbrt.html#trigeminal-neuralgia"><i class="fa fa-check"></i><b>21.10.9</b> Trigeminal neuralgia</a></li>
</ul></li>
<li class="chapter" data-level="21.11" data-path="sbrt.html"><a href="sbrt.html#dose-fall-off"><i class="fa fa-check"></i><b>21.11</b> Dose fall-off</a></li>
<li class="chapter" data-level="21.12" data-path="sbrt.html"><a href="sbrt.html#required-measurements-for-commissioning-a-srssbrt-program"><i class="fa fa-check"></i><b>21.12</b> Required measurements for commissioning a SRS/SBRT program</a></li>
</ul></li>
<li class="chapter" data-level="22" data-path="hdr.html"><a href="hdr.html"><i class="fa fa-check"></i><b>22</b> HDR</a><ul>
<li class="chapter" data-level="22.1" data-path="hdr.html"><a href="hdr.html#hdr-vs.ldr"><i class="fa fa-check"></i><b>22.1</b> HDR vs. LDR</a></li>
<li class="chapter" data-level="22.2" data-path="hdr.html"><a href="hdr.html#hdr-qa"><i class="fa fa-check"></i><b>22.2</b> HDR-QA</a><ul>
<li class="chapter" data-level="22.2.1" data-path="hdr.html"><a href="hdr.html#daily-device-qa"><i class="fa fa-check"></i><b>22.2.1</b> Daily (device) QA</a></li>
<li class="chapter" data-level="22.2.2" data-path="hdr.html"><a href="hdr.html#pretreatment-qa-tg-59"><i class="fa fa-check"></i><b>22.2.2</b> Pretreatment QA (TG-59)</a></li>
<li class="chapter" data-level="22.2.3" data-path="hdr.html"><a href="hdr.html#hdr-source-change"><i class="fa fa-check"></i><b>22.2.3</b> Source change</a></li>
<li class="chapter" data-level="22.2.4" data-path="hdr.html"><a href="hdr.html#medical-events"><i class="fa fa-check"></i><b>22.2.4</b> Medical Events</a></li>
</ul></li>
<li class="chapter" data-level="22.3" data-path="hdr.html"><a href="hdr.html#sources"><i class="fa fa-check"></i><b>22.3</b> Sources</a></li>
<li class="chapter" data-level="22.4" data-path="hdr.html"><a href="hdr.html#treatment-sites-1"><i class="fa fa-check"></i><b>22.4</b> Treatment sites</a><ul>
<li class="chapter" data-level="22.4.1" data-path="hdr.html"><a href="hdr.html#cervical"><i class="fa fa-check"></i><b>22.4.1</b> Cervical cancer</a></li>
<li class="chapter" data-level="22.4.2" data-path="hdr.html"><a href="hdr.html#breast"><i class="fa fa-check"></i><b>22.4.2</b> Breast</a></li>
<li class="chapter" data-level="22.4.3" data-path="hdr.html"><a href="hdr.html#prostate"><i class="fa fa-check"></i><b>22.4.3</b> Prostate</a></li>
<li class="chapter" data-level="22.4.4" data-path="hdr.html"><a href="hdr.html#endometrial-cancer"><i class="fa fa-check"></i><b>22.4.4</b> Endometrial cancer</a></li>
</ul></li>
<li class="chapter" data-level="22.5" data-path="hdr.html"><a href="hdr.html#oncentra-planning"><i class="fa fa-check"></i><b>22.5</b> Oncentra planning</a></li>
<li class="chapter" data-level="22.6" data-path="hdr.html"><a href="hdr.html#saftey-and-shielding-design"><i class="fa fa-check"></i><b>22.6</b> Saftey and shielding design</a></li>
<li class="chapter" data-level="22.7" data-path="hdr.html"><a href="hdr.html#solutions-1"><i class="fa fa-check"></i><b>22.7</b> Solutions</a></li>
</ul></li>
<li class="chapter" data-level="23" data-path="implants.html"><a href="implants.html"><i class="fa fa-check"></i><b>23</b> Implants</a><ul>
<li class="chapter" data-level="23.1" data-path="implants.html"><a href="implants.html#isotopes-1"><i class="fa fa-check"></i><b>23.1</b> Isotopes</a></li>
<li class="chapter" data-level="23.2" data-path="implants.html"><a href="implants.html#patient-release"><i class="fa fa-check"></i><b>23.2</b> Patient Release</a></li>
<li class="chapter" data-level="23.3" data-path="implants.html"><a href="implants.html#prostate-implants"><i class="fa fa-check"></i><b>23.3</b> Prostate implants</a></li>
<li class="chapter" data-level="23.4" data-path="implants.html"><a href="implants.html#y90"><i class="fa fa-check"></i><b>23.4</b> TheraSphere</a></li>
<li class="chapter" data-level="23.5" data-path="implants.html"><a href="implants.html#eye-plaque-planning"><i class="fa fa-check"></i><b>23.5</b> Eye plaque planning</a></li>
</ul></li>
<li class="chapter" data-level="24" data-path="ivbt.html"><a href="ivbt.html"><i class="fa fa-check"></i><b>24</b> Intravascular BT</a></li>
<li class="chapter" data-level="25" data-path="igrt.html"><a href="igrt.html"><i class="fa fa-check"></i><b>25</b> IGRT</a></li>
<li class="chapter" data-level="26" data-path="cyber-knife.html"><a href="cyber-knife.html"><i class="fa fa-check"></i><b>26</b> Cyber Knife</a><ul>
<li class="chapter" data-level="26.1" data-path="cyber-knife.html"><a href="cyber-knife.html#tg-180"><i class="fa fa-check"></i><b>26.1</b> TG 180</a></li>
</ul></li>
<li class="chapter" data-level="27" data-path="proton.html"><a href="proton.html"><i class="fa fa-check"></i><b>27</b> Proton RT</a></li>
<li class="chapter" data-level="" data-path="references.html"><a href="references.html"><i class="fa fa-check"></i>References</a></li>
<li class="chapter" data-level="28" data-path="it.html"><a href="it.html"><i class="fa fa-check"></i><b>28</b> Information Technology</a><ul>
<li class="chapter" data-level="28.1" data-path="it.html"><a href="it.html#it-basics"><i class="fa fa-check"></i><b>28.1</b> IT basics</a></li>
<li class="chapter" data-level="28.2" data-path="it.html"><a href="it.html#dicom"><i class="fa fa-check"></i><b>28.2</b> DICOM</a></li>
<li class="chapter" data-level="28.3" data-path="it.html"><a href="it.html#database-basics"><i class="fa fa-check"></i><b>28.3</b> Database basics</a></li>
<li class="chapter" data-level="28.4" data-path="it.html"><a href="it.html#programming"><i class="fa fa-check"></i><b>28.4</b> Programming</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">MP</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="hdr" class="section level1">
<h1><span class="header-section-number">Chapter 22</span> HDR</h1>
<div id="hdr-vs.ldr" class="section level2">
<h2><span class="header-section-number">22.1</span> HDR vs. LDR</h2>
<p>LDR: well-established treatment; standard doses, plan, and treatmetn time<br />
HDR: Outpatient treatment, short administration time, minimal staff exposure, standard source strength, and dose optimization<span class="citation">(Stewart and Viswanathan, <a href="#ref-stewart_current_2006">2006</a>)</span><span class="citation">(Showalter, n.d.)</span></p>
<p>Up to date, commmon indications in practice are include:</p>
<ul>
<li><strong>GYN</strong> (cervical <span class="citation">(Liu et al., <a href="#ref-liu_high_2014">2014</a>; Wang et al., <a href="#ref-wang_high_2010">2010</a>)</span>, uterine, vaginal, vulvar)</li>
<li><strong>Prostate</strong> (monotherapy or boost)</li>
<li><strong>Breast</strong> (accelerated partial breast irradiation)</li>
<li>possible Sarcoma, skin, esophagus, and bile duct</li>
</ul>
<p>In recent review paper, authors <span class="citation">(Liu et al., <a href="#ref-liu_high_2014">2014</a>)</span> showed that there is no difference in OS, DSS, LC, nodal occurrence, distance occurrence was found between LDR and HDR (from a meta-analysis of 4 clinical trials in <em>Cochrane database</em> with a total of 1265 patients with advanced cervical cancer), but HDR is more convenient and accurate.<a href="#fn19" class="footnoteRef" id="fnref19"><sup>19</sup></a></p>
</div>
<div id="hdr-qa" class="section level2">
<h2><span class="header-section-number">22.2</span> HDR-QA</h2>
<blockquote>
<p>What am I testing and why am I testing it?</p>
<p>— Susan Richardson 2017 AAPM <a href="https://www.aapm.org/education/vl/vl.asp?id=12300">talk</a> EDBCCA should be B and A</p>
</blockquote>
<div id="daily-device-qa" class="section level3">
<h3><span class="header-section-number">22.2.1</span> Daily (device) QA</h3>
<p>According <a href="https://www.nrc.gov/reading-rm/doc-collections/cfr/part035/part035-0643.html">10 CFR35.643 “Periodic spot-checks for remote afterloader units”“</a>, the following tests are required:</p>
<ol style="list-style-type: decimal">
<li>Electrical interlocks at entrance to room.</li>
<li>Source exposure indicator lights on the after loader, control console, and in the facility.</li>
<li>Viewing and intercom systems.</li>
<li>Emergency response equipment.</li>
<li>Radiation monitors to indicate source position (<span class="math inline">\(\pm1\)</span> mm) - <code>this test does not gurantee you the correct treatmetn position in the patient (e.g vaginal cylinder slid out 2 cm between imaging and treatment).</code></li>
<li>Timer accuracy (<span class="math inline">\(\pm1\)</span> s).</li>
<li>Clock (date and time) in unit’s computer.</li>
<li>Decayed source activity in unit’s computer.</li>
</ol>
<p>The <font color="Salmon">autheried medical physicist</font> (AMP) should review the daily QA within <strong>15 days</strong>. The APM shall notify the licensee as soon as possible in writing of the results of each spot-check.</p>
</div>
<div id="pretreatment-qa-tg-59" class="section level3">
<h3><span class="header-section-number">22.2.2</span> Pretreatment QA (TG-59)</h3>
<ol style="list-style-type: decimal">
<li>Two people (therapists?) should check proper <strong>connection of catheters</strong> to the HDR unit and that the transfer tubes are free of kinks.</li>
<li>The emergency kit and source container are available.</li>
<li>Survey meter and/or GM-counter is present and operational. - <code>The patient may have had a nuclear medicine scan prior to the treatment, causing an elevated reading. thus a **pre-treatment survey** is conducted though not listed in TG-59.</code></li>
<li>The <strong>length</strong> of transfer tube and applicator (catheters) are correct.</li>
<li>Check applicator positioning. How do physicians check this item without image verification?</li>
<li>Treatment documentation review.
<ol style="list-style-type: lower-alpha">
<li>Signed prescription and plan.</li>
<li>Second check has been performed. (use emipircal values)</li>
<li>Plan agrees with prescription.</li>
<li>Plan is consistent with previous fractions if applicable.</li>
<li>Dwell positions and times in plan agree with what is programmed on the treatment console.</li>
</ol></li>
<li>Patient identity confirmed by two methods.</li>
</ol>
<p>At current practice, a <strong>check-list</strong> is used by physicists for pretrement plan QA and a time-out is conducted prior to initiating the treatment.</p>
</div>
<div id="hdr-source-change" class="section level3">
<h3><span class="header-section-number">22.2.3</span> Source change</h3>
<p>The half-life time is about 74 days, so the old source is sawpped with a new source about every 3 months. The activity of the new source is normally about <strong>10 Ci</strong>. According to Eq. <a href="brachy.html#eq:sk">(15.1)</a> and Eq. <a href="brachy.html#eq:exposure">(15.2)</a>, the source strength is equal to 41100 U (<span class="math inline">\(S_k = 10,000\ (mCi) \times 4.69 \left(\frac{{R\cdot cm}^2}{mCi\cdot hr} \right) \times 0.876 \left(\frac{cGy}{R}\right)\)</span>). This quantity will be verified by an AMP using NIST tracable well chamber and electrometer, and then enterred in the treatment planning system for dose calculation. The engineering from HDR afterloader vendor also verifies the source using their own equipment.</p>
<ol style="list-style-type: decimal">
<li>Verify the source cable <strong>positioning accuracy</strong> at two different programmed positions (1205 mm and 1400 mm) before the vendor engineering leaves (using GYN transfer tube).</li>
<li>Although the well chamber and electrometer is still within 2-year calibration period, we always do <strong>consistence check</strong> using a NIST-traceble Cs-137 source (we actually checked with 2 Cs-137 sources provided by our RSO).</li>
<li>Switch a physics QA transfer tube and insert a catheter into Ir-192 insert.</li>
<li>Measure current at 5 positions (1195 mm, 1200 mm, 1205 mm, 1210 mm, and 1215 mm) and take an average</li>
<li>Check time-dose linearity</li>
<li>Check stopwatch accuracy (100 s)</li>
<li>Check transfer tube connection error</li>
<li>Switch emergency power switch</li>
</ol>
</div>
<div id="medical-events" class="section level3">
<h3><span class="header-section-number">22.2.4</span> Medical Events</h3>
<ul>
<li><a href="http://www.nrc.gov/reading-rm/doccollections/nuregs/brochures/br0117/">Errors on NRC website</a></li>
<li><a href="(http://chapter.aapm.org/GLC/media/2011/tollenaar.pdf)">Wisconsin</a> The purpose of reporting a medical event is to improve patients’ safety. 2017 AAPM Annual Meeting <a href="https://www.aapm.org/education/sams/Default.asp?v=true&amp;mid=127&amp;qid=2540">An Interactive Safety Session for New Brachytherapy Practitioners</a>ED<em>C</em>CCA</li>
</ul>
</div>
</div>
<div id="sources" class="section level2">
<h2><span class="header-section-number">22.3</span> Sources</h2>
<p>A comprehensive seed data source can be found from a <a href="http://www.physics.carleton.ca/clrp/seed_database">database</a> provided by Carleton University</p>
<p>Because <a href="https://www.estro.org/about/governance-organisation/committees-activities/tg43-ir-192-hdr">Ir-192</a> has much higher <font color="Salmon">special activity</font><a href="#fn20" class="footnoteRef" id="fnref20"><sup>20</sup></a> than most other isotopes, it is now the mostly used radio-isotope for HDR treatment. The higher the special activity means that the Ir-192 can be made with small physial dimension but still provide high radioactivity.</p>
<p>Recently, Co-60 has been used as the HDR sources.<span class="citation">(Nath et al., <a href="#ref-nath_guidelines_2016">2016</a>)</span></p>
</div>
<div id="treatment-sites-1" class="section level2">
<h2><span class="header-section-number">22.4</span> Treatment sites</h2>
<p>The treatment guidelines can be found at American Brachytherapy Society (ABS) <a href="https://www.americanbrachytherapy.org/guidelines/">website</a>.</p>
<div id="cervical" class="section level3">
<h3><span class="header-section-number">22.4.1</span> Cervical cancer</h3>
<p>The ABS recommends the use of brachytherapy as a component (after EBRT) of the definitive treatment of locally advanced cervical carcinoma. <span class="citation">(Viswanathan and Thomadsen, <a href="#ref-viswanathan_american_2012">2012</a>, <span class="citation">Viswanathan et al. (<a href="#ref-viswanathan_american_2012-1">2012</a>)</span>)</span></p>
<p>Based on the <a href="https://www.aapm.org/education/vl/vl.asp?id=4077%5D">talk</a> by J. Schwarz, treating cervial cancer has progressed</p>
<ul>
<li>1903 Stockholm and Paris</li>
<li>1938 Manchester – point A</li>
<li>1953 Point A revision</li>
<li>1985 ICRU 38</li>
<li>1987 more point A updates</li>
<li>2000 GEC-ESTRO
<ul>
<li>D90, D100 for dose prescription</li>
<li>D2cc bladder, rectum, and sigmoid</li>
</ul></li>
<li>2004 GTV and CTV delineation (<strong>MRI</strong>)</li>
<li>2005 GEC-ESTRO recommendation for IGRT brachytherapy</li>
<li>…</li>
</ul>
<p><font color="#27AE60"><i>Why is MRI preferred to CT for target delineation?</i></font></p>
<ul>
<li>MRI has been soft tissue contrast.</li>
<li>MRI has better overlap with FPG-PET volumes. (?more clinical[^clinical] importance)</li>
<li>Improved overall survivial for large tumours (&gt;5 cm), 28% versus 58% (p = 0.003), when the target is drawn on MRI.<span class="citation">(Pötter et al., <a href="#ref-potter_clinical_2007">2007</a>)</span></li>
</ul>
<p><font color="#27AE60">What are the targets in MR-based HDR??</font></p>
<p>Targets include gross tumor volume (diagnosis) (GTV<sub>D</sub>), gross tumor volume (brachy) (GTV<sub>B1</sub>, GTV<sub>B2</sub>, …), high risk CTV (HR CTV<sub>B1</sub>, HR CTV<sub>B2</sub>, …), and intermediate risk CTV (IR CTV<sub>B1</sub>, IR CTV<sub>B2</sub>, …). The IR CTV include the microscopic disease, IR CTV = HR CTV + 5-15 mm margin. The details about target delineation and dose can be found in the recommendations from GEC-ESTRO Working Group (I)<span class="citation">(Haie-Meder et al., <a href="#ref-haie-meder_recommendations_2005">2005</a>)</span>.</p>
<p><strong>Idea</strong>: availability of commercial dummy sources for MRI is limited.</p>
<p><font color="#27AE60"><i>What are the recommendations for using the MR-compatible applicators during MRI?</i></font></p>
<p>The choice of MR sequence is essential for optimal visualisation of the applicator (plastic or titanium):<span class="citation">(Dimopoulos et al., <a href="#ref-dimopoulos_recommendations_2012">2012</a>; Haack et al., <a href="#ref-haack_applicator_2009">2009</a>)</span></p>
<ul>
<li>Plastic has weak signal on T2; use of markers</li>
<li>Titanium has (induced) susceptibility artifact, and thus more distortions for higher magnetic strength; worse on T2; T1 is more suitable (? Why Titanium is MR compatible? )</li>
<li>If an applicator has been shown to be MR conditional for a 1.5T MRI, then it does <strong>not</strong> mean that it can be safely used in a 3T system without the need for further testing. CT still provides best imaging for applicator in terms of spatial accuracy (1 mm on CT vs. 1-2 mm on MRI for the localization of first dwell position) and artifacts.</li>
</ul>
</div>
<div id="breast" class="section level3">
<h3><span class="header-section-number">22.4.2</span> Breast</h3>
<p>ABS acceptability criteria for APBI</p>
<ul>
<li>Age: <span class="math inline">\(\ge\)</span> 50 year old</li>
<li>Size: <span class="math inline">\(\le\)</span> 3 cm</li>
<li>Histology: All invasive subtypes and DCIS</li>
<li>Estrogen receptor: +/-</li>
<li>Surgical margin: -</li>
<li>Lymphovasucular space invasion: not present</li>
<li>Nodal status: -</li>
</ul>
<p>Treatment planning</p>
<ul>
<li>34 Gy in 10 fractions twice daily</li>
<li>PTV<sub>Eval</sub> + D90% &gt;= 90% + V150 &lt; 50 cm<sup>3</sup> + V200 &lt; 10 cm<sup>3</sup> + Skin dose &lt; 145% of prescription</li>
</ul>
<p>They are slightly different from ASTRO Consensus Statement 2009.</p>
</div>
<div id="prostate" class="section level3">
<h3><span class="header-section-number">22.4.3</span> Prostate</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111004004">ABS consensus guidelines for high-dose-rate prostate brachytherapy</a></p>
<p>Monotherapy: 13.5 Gy <span class="math inline">\(\times\)</span> 2 fractions (NCCN)</p>
</div>
<div id="endometrial-cancer" class="section level3">
<h3><span class="header-section-number">22.4.4</span> Endometrial cancer</h3>
<p><a href="https://www.sciencedirect.com/science/article/pii/S1538472111003874?via%3Dihub">ABS consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy</a></p>
<ul>
<li>Dose fractionation: 7Gy <span class="math inline">\(\times\)</span> 3 prescribed to 0.5 cm is a common fractionation scheme with active length of 5 cm (<span class="math inline">\(\color{Purple} {\text{Are we treating vaginal cuff or the whole vigina?}}\)</span>)</li>
<li>the standard applicator is a segmented cylinder with one central catheter; the <strong>largest diameter</strong> cylinder that patient can tolerate is used to minimize the air gap between cylinder and vagina and to avoid rapid dose fall-off.</li>
</ul>
</div>
</div>
<div id="oncentra-planning" class="section level2">
<h2><span class="header-section-number">22.5</span> Oncentra planning</h2>
<p>The workflow for the latest Oncentra planning system looks like</p>
<div class="figure" style="text-align: center"><span id="fig:oncentra-wf"></span>
<img src="figures/oncentra-workflow.png" alt="Oncentra workflow (from Elekta online [document](https://www.elekta.com/dam/jcr:0361c151-4eb5-4017-a5b6-6a35c4398671/Oncentra%C2%AE%20Brachy%20brochure.pdf))" width="80%" />
<p class="caption">
Figure 22.1: Oncentra workflow (from Elekta online <a href="https://www.elekta.com/dam/jcr:0361c151-4eb5-4017-a5b6-6a35c4398671/Oncentra%C2%AE%20Brachy%20brochure.pdf">document</a>)
</p>
</div>
<p>The overall planning and QA mindmap</p>
<div class="figure" style="text-align: center"><span id="fig:hdr-map"></span>
<img src="figures/HDR-map.png" alt="HDR planning and QA mindmap"  />
<p class="caption">
Figure 22.2: HDR planning and QA mindmap
</p>
</div>
</div>
<div id="saftey-and-shielding-design" class="section level2">
<h2><span class="header-section-number">22.6</span> Saftey and shielding design</h2>
<p>Typical room ~ 60 cm concret</p>
<p><strong>Q3 TG43U </strong> d)</p>
<p>Using Eq. @ref(eq.tg43) or TG-43U1 2D Brachytherapy dosimetry formalism,</p>
<span class="math display">\[\begin{equation}
\begin{aligned}
   \dot D(r, \theta) &amp;= \Lambda\cdot S_k \frac{G_L(r, \theta)}{G_L(r=1cm,\theta=90^o)} \cdot g_L(r, \theta)\cdot F(r,\theta)\\
   &amp;=1.12\ cGy/(h\cdot U)\cdot4.11\times10^4\text{U}\cdot1.023\cdot1\\
   &amp;=\boxed{13.1\ cGy/s}
\end{aligned}

\end{equation}\]</span>
The half-life time of Ir-192 is about 74 days, so activity after 90 days (Eq. (<a href="nut.html#eq:decay2">(2.2)</a>)) is
<span class="math display">\[\begin{equation*}
    A_2 = A_02^{-t/T_{1/2}}=A_02^{-90/74}=0.43A_1
\end{equation*}\]</span>
<p>To maintain the prescribed dose (<span class="math inline">\(\dot D_1 \Delta t_1 = \dot D_2 \Delta t_2\)</span> and <span class="math inline">\(A \propto \dot D\)</span>, the dwell time <span class="math inline">\(\Delta t_2\)</span> will be</p>
<span class="math display">\[\begin{equation*} 
{\Delta t_2 = \frac{\dot D_1}{\dot D_2} \Delta t_1 = \frac{\dot A_1}{\dot A_2} \Delta t_1 = \frac{1}{0.43}\times 16 \text{ min} \ \times 80\% = \boxed{29.7 \text{ min}}}
\end{equation*}\]</span>
<p>The total treatment time will be <span class="math inline">\(29.7 + 16\times20\%=\boxed{33\ \text{minutes}}\)</span>.</p>
</div>
<div id="solutions-1" class="section level2">
<h2><span class="header-section-number">22.7</span> Solutions</h2>
<p><code>Q4 Afterloader QA a)</code><br />
<code>Q5 Shiedling b)</code><br />
<code>Q6 Impact of decay on treatment timee</code><br />
<code>Q7 c)</code><br />
<code>Q8 c)</code><br />
<code>Q9 b)</code> <code>Q10 a) but esophagus cancer is also treated with HDR but with less indication</code><br />
<code>Q11 b)</code><br />
<code>Q12 d)</code></p>
<p>Perceive and Believe Stay Calm Think, plan, and analyze Take decisive action Celebrate success</p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references">
<div id="ref-stewart_current_2006">
<p>Stewart, A.J., Viswanathan, A.N., 2006. Current controversies in high-dose-rate versus low-dose-rate brachytherapy for cervical cancer. Cancer 107, 908–915. doi:<a href="https://doi.org/10.1002/cncr.22054">10.1002/cncr.22054</a></p>
</div>
<div id="ref-liu_high_2014">
<p>Liu, R., Wang, X., Tian, J.H., Yang, K., Wang, J., Jiang, L., Hao, X.Y., 2014. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database Syst Rev CD007563. doi:<a href="https://doi.org/10.1002/14651858.CD007563.pub3">10.1002/14651858.CD007563.pub3</a></p>
</div>
<div id="ref-wang_high_2010">
<p>Wang, X., Liu, R., Ma, B., Yang, K., Tian, J., Jiang, L., Bai, Z.G., Hao, X.Y., Wang, J., Li, J., Sun, S.L., Yin, H., 2010. High dose rate versus low dose rate intracavity brachytherapy for locally advanced uterine cervix cancer. Cochrane Database of Systematic Reviews. doi:<a href="https://doi.org/10.1002/14651858.CD007563.pub2">10.1002/14651858.CD007563.pub2</a></p>
</div>
<div id="ref-nath_guidelines_2016">
<p>Nath, R., Rivard, M.J., DeWerd, L.A., Dezarn, W.A., Thompson Heaton, H., Ibbott, G.S., Meigooni, A.S., Ouhib, Z., Rusch, T.W., Siebert, F.-A., Venselaar, J.L.M., 2016. Guidelines by the AAPM and GEC-ESTRO on the use of innovative brachytherapy devices and applications: Report of task group 167: Task group 167: Innovative brachytherapy devices and applications. Medical Physics 43, 3178–3205. doi:<a href="https://doi.org/10.1118/1.4951734">10.1118/1.4951734</a></p>
</div>
<div id="ref-viswanathan_american_2012">
<p>Viswanathan, A.N., Thomadsen, B., 2012. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. part i: General principles. Brachytherapy, Special issue: American brachytherapy society guidelines for prostate and gynecology 11, 33–46. doi:<a href="https://doi.org/10.1016/j.brachy.2011.07.003">10.1016/j.brachy.2011.07.003</a></p>
</div>
<div id="ref-viswanathan_american_2012-1">
<p>Viswanathan, A.N., Beriwal, S., De Los Santos, J.F., Demanes, D.J., Gaffney, D., Hansen, J., Jones, E., Kirisits, C., Thomadsen, B., Erickson, B., 2012. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. part II: High-dose-rate brachytherapy. Brachytherapy, Special issue: American brachytherapy society guidelines for prostate and gynecology 11, 47–52. doi:<a href="https://doi.org/10.1016/j.brachy.2011.07.002">10.1016/j.brachy.2011.07.002</a></p>
</div>
<div id="ref-potter_clinical_2007">
<p>Pötter, R., Dimopoulos, J., Georg, P., Lang, S., Waldhäusl, C., Wachter-Gerstner, N., Weitmann, H., Reinthaller, A., Knocke, T.H., Wachter, S., Kirisits, C., 2007. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiotherapy and Oncology 83, 148–155. doi:<a href="https://doi.org/10.1016/j.radonc.2007.04.012">10.1016/j.radonc.2007.04.012</a></p>
</div>
<div id="ref-haie-meder_recommendations_2005">
<p>Haie-Meder, C., Pötter, R., Van Limbergen, E., Briot, E., De Brabandere, M., Dimopoulos, J., Dumas, I., Hellebust, T.P., Kirisits, C., Lang, S., Muschitz, S., Nevinson, J., Nulens, A., Petrow, P., Wachter-Gerstner, N., 2005. Recommendations from gynaecological (GYN) GEC-ESTRO working group☆ (i): Concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy and Oncology 74, 235–245. doi:<a href="https://doi.org/10.1016/j.radonc.2004.12.015">10.1016/j.radonc.2004.12.015</a></p>
</div>
<div id="ref-dimopoulos_recommendations_2012">
<p>Dimopoulos, J.C.A., Petrow, P., Tanderup, K., Petric, P., Berger, D., Kirisits, C., Pedersen, E.M., Limbergen, E. van, Haie-Meder, C., Pötter, R., 2012. Recommendations from gynaecological (GYN) GEC-ESTRO working group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiotherapy and Oncology 103, 113–122. doi:<a href="https://doi.org/10.1016/j.radonc.2011.12.024">10.1016/j.radonc.2011.12.024</a></p>
</div>
<div id="ref-haack_applicator_2009">
<p>Haack, S., Nielsen, S.K., Lindegaard, J.C., Gelineck, J., Tanderup, K., 2009. Applicator reconstruction in MRI 3D image-based dose planning of brachytherapy for cervical cancer. Radiotherapy and Oncology 91, 187–193. doi:<a href="https://doi.org/10.1016/j.radonc.2008.09.002">10.1016/j.radonc.2008.09.002</a></p>
</div>
</div>
<div class="footnotes">
<hr />
<ol start="19">
<li id="fn19"><p>Excerpt <em>“Theoretically, HDR has a lower therapeutic ratio than LDR because of the short duration of the treatments.”</em>&quot; - Practical Radiation Oncology Physics, <span class="citation">(Dieterich et al., <a href="#ref-dieterich_practical_2016">2016</a>)</span> Chapter “Intracavitary Brachytherapy”<a href="hdr.html#fnref19">↩</a></p></li>
<li id="fn20"><p>The special activity (SA) is defined as the activity per mass. It depends on half lifetime and atomic number, <span class="math inline">\(SA \propto \frac{1}{T_{1/2}\cdot A}\)</span>. For example, <span class="math inline">\(\frac{SA_{Co}}{SA_{Ir}} = \frac{74\ days \times 192}{5\ years \times 60} \approx 0.13\)</span>. Wait a second, how about SA of I-125? Although I-125 can have higher SA than Ir-192, the energy of I-125 is just too low for enough tissue penetration.<a href="hdr.html#fnref20">↩</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="sbrt.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="implants.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/lunr.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"google": false,
"linkedin": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": null,
"download": ["MP.pdf"],
"toc": {
"collapse": "subsection",
"scroll_highlight": true
},
"toolbar": {
"position": "fixed"
},
"search": true
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "";
    if (src === "" || src === "true") src = "https://cdn.bootcss.com/mathjax/2.7.1/MathJax.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:" && /^https?:/.test(src))
      src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
